VRDN NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Viridian Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 18.92 USD
-1.8% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -14.3% below the Trend Line and sits at 27.2% of its 52-week range. The latest completed week returned -1.8%, after a -2.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 60/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 35 out of 100
Latest Close 18.92 USD 31 Jul 2026
1W Return -1.8% latest completed week
4W Return -2.5% short-term follow-through
12W Return 13.9% quarterly tape
Trend Breadth 61.5% 32 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.8% Latest completed week; four-week move -2.5%. Indicator stack 34/90 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bearish 60/100 conviction; expected move 6.5%. News sentiment 56/100 66 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -14.3% below the Trend Line and sits at 27.2% of its 52-week range. The latest completed week returned -1.8%, after a -2.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1612-week average 0.09

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.16Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.5% over four weeks, 13.9% over 12 weeks, and 8.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-1.8%
4W-2.5%
12W13.9%
26W-42.7%
52W8.7%
Active trend streak0 weeks
Active weeks in one year32
Trend breadth61.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.55Latest activity-pressure read.
Pressure change382.1%Four-week change in activity pressure.
Leadership-25.92Latest relative-leadership reading.
RS change4.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength31/100Blend of value, momentum, and quality. Underlying universe rank 70; rank 1 is best.
Value41/100Relative valuation strength. Underlying universe rank 60; rank 1 is best.
Quality40/100Profitability and accounting quality. Underlying universe rank 61; rank 1 is best.
Momentum42/100Medium-term price momentum. Underlying universe rank 59; rank 1 is best.
Growth42/100Revenue and earnings growth. Underlying universe rank 59; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
30.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-14.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
99.4%
Gross profit retained from each unit of revenue.
Operating margin
-492.7%
Operating profit retained from revenue.
Free-cash-flow margin
-427.2%
Free cash flow generated from revenue.
Return on invested capital
-51.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-16.3%
Net share repurchases relative to market value.
Shareholder yield
-16.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

VRDN shows bearish options pressure with a 60/100 conviction score, put-call volume ratio of 6.44, expected move of 6.5%, and Sharemaestro trend signal inactive.

Conviction60/100
Expected move6.5%
Put/call volume6.44
Pressure-85
Speculation21
Volatility45
Trend agreement57
Open options detail
Insider activity7 / 0

7 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 66 relevant articles.

19 positive · 43 neutral · 4 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move6.5%Nearest-chain priced movement where available.
52-week drawdown-44.8%Distance below the 52-week high.
13-week volatility8.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+23.8%Week of 8 May.
Worst week-31.2%Week of 3 Apr.
Latest week-1.8%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains8
Flat weeks0
Modest losses5
Sharp losses8
Recent vol8.1%13-week weekly-return volatility.
Base vol8.5%52-week weekly-return volatility.
Up/down split31/21Count of positive and negative weeks in the 52-week window.
Average skew5.4% / -6.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape34/100

Trend, activity pressure, participation, and risk combine to a 34/100 tape read.

 Indicator analysis18/100

Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 0/12.

Activity pressure 0.16; No reversal markers Factors37/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 89; Small Cap Core rank 60 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options36/100

VRDN shows bearish options pressure with a 60/100 conviction score, put-call volume ratio of 6.44, expected move of 6.5%, and Sharemaestro trend signal inactive.

Bearish · Put-side pressure · Expected move 6.5% Sentiment56/100

Weighted news tone is neutral across 66 relevant articles.

How Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors Insiders7 / 0

7 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202618.92 USD-1.8%22.08 USD18.98 USD0.55-25.927.7MOff
24 Jul 202619.27 USD6.9%22.47 USD18.97 USD0.50-24.298.8MOff
17 Jul 202618.03 USD-8.7%22.89 USD18.97 USD0.35-30.388.1MOff
10 Jul 202619.74 USD1.8%23.35 USD18.99 USD0.12-27.0810.4MOff
3 Jul 202619.40 USD8.4%23.77 USD19.00 USD-0.19-27.1816.3MOff
26 Jun 202617.90 USD7.6%24.19 USD19.03 USD-0.52-32.2713.2MOff
19 Jun 202616.63 USD1.7%24.66 USD19.07 USD-0.75-39.939.0MOff
12 Jun 202616.35 USD3.6%25.12 USD19.12 USD-0.88-39.546.5MOff
5 Jun 202615.78 USD-10.4%25.53 USD19.19 USD-0.99-40.538.4MOff
29 May 202617.62 USD2.2%25.92 USD19.25 USD-1.02-36.764.9MOff
22 May 202617.24 USD2.5%26.12 USD19.30 USD-1.21-36.4312.0MOff
15 May 202616.82 USD1.3%26.29 USD19.34 USD-1.41-37.3211.6MOff
8 May 202616.61 USD23.8%26.53 USD19.38 USD-1.54-38.3440.2MOff
1 May 202613.42 USD-2.3%26.68 USD19.42 USD-1.59-47.499.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.